A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Latest Information Update: 03 May 2024
At a glance
- Drugs Baricitinib (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions; Registrational
- Acronyms JUVE-X
- Sponsors Eli Lilly and Company
- 18 Oct 2022 Planned End Date changed from 6 Dec 2027 to 18 Dec 2030.
- 18 Oct 2022 Planned primary completion date changed from 6 Dec 2027 to 18 Dec 2030.
- 22 Sep 2020 Planned number of patients changed from 236 to 410.